Jubilant Biosys

Delivering the Added Dimension in Drug Discovery Services

In-vivo Pharmacology

The In-vivo Pharmacology & Biology department at Jubilant has state-of-the-art infrastructure and the expertise to conduct PK-PD and efficacy studies in various disease models related to oncology, metabolic disorder, pain, inflammation and respiratory disease therapeutic areas.

Immunocompromised strains of mice, rodents and rabbits are housed in our dedicated animal facility for in-vivo pharmacology. Animal studies for in-vivo pharmacology are conducted under the guidance of the Institutional Ethics Committee and are overseen by experts in each of the models and disease areas.

Pain Models and Biomarkers
for In-vivo Pharmacology

Nociceptive Pain Models

  • Formalin induced paw licking and biting in rats
  • Acetic acid writhing test in mice
  • Hot plate model
  • Tail flick model

Inflammatory Pain Models

  • Carrageenan induced inflammation (paw volume, paw thickness, thermal hyperalgesia in rats)
  • CFA induced thermal hyperalgesia / mechanical hyperalgesia / allodynia in rats
  • Collagen-induced arthritis (CIA) in DBA mice

Neuropathic Pain Models

  • CCI-induced neuropathic pain in rats (Bennet & Xie model)
  • L5/L6 ligation-induced neuropathic (Chung’s model)
  • Streptozotocin (STZ)-induced diabetic neuropathy in rats
  • Chemotherapy (paclitaxel) induced neuropathic pain

Biomarker Analysis

  • INF-? measurement from plasma and media
  • IL1-ß from culture media
  • TNF-a from plasma and media

Target Engagement

  • Coupled with biomarker analysis for in-vitro / in-vivo correlation and human dose projection

Oncology Models and Biomarkers for In-vivo Pharmacology

Sucutaneous Xenograft Models

  • Lung (NCI-H82, HCC827, Calu-6)
  • Breast (MDA-MB-231)
  • Colon (HT-29, Colo-205, HCT116)
  • Prostate (PC3, DU-145, LNCaP)
  • Gastric (MKN-45)
  • Pancreatic (PANC-1)
  • Others (A431, U-87 MG, B16-F10)

Orthotopic Xenograft Models

  • Breast and prostate

Metastatic Xenograft Models

  • Lung and liver

Syngeneic Tumor Models

  • B16F-10

Matrigel Plug Angiogenesis Model

PK-PD Models

  • Xenograft tumors
  • Western Blot, ELISA, MSD and FACS based PD marker assessment in tumor tissue
  • Correlation of PK, PD and efficacy
  • Projection of therapeutic index and efficacious human dose

Metabolic Disorder Models and Biomarkers for In-vivo Pharmacology

Screening Models in Mice and Rats

  • OLTT
  • Diet induced obesity (DIO)
  • Incretin and endocrine secretion – GLP-1, PYY/CCK

Models Under Development

  • Hyperinsulinemic clamp
  • In-vivo adipolysis
  • Fatty acid oxidation
  • Hypercholesterlemia / dyslipidemia

Biomarker Analysis

  • Apo B, insulin, GLP-1, glucagon, adiponectin, triglyceride and cholesterol
  • Gene expression analysis in cells and ex-vivo tissues

Dydlipidemia and Hyperglycemia Models

  • db/db & ab/ab
  • ZDF & zucker fa/fa
  • Streptozotocin induced diabetes

Our experienced in-vivo pharmacology scientific team has cornerstone expertise in helping clients with in-vivo biology solutions.